Adolescents living with HIV are at higher risk of death and loss to follow up from care: Analysis of cohort data from eight health facilities in Ethiopia
Autoři:
Degu Jerene aff001; Workeabeba Abebe aff002; Kefyalew Taye aff003; Andrea Ruff aff004; Inger Hallstrom aff005
Působiště autorů:
KNCV Tuberculosis Foundation, The Hague, The Netherlands
aff001; Addis Ababa University, Department of Pediatrics and Child Health, Addis Ababa, Ethiopia
aff002; Hawassa University, Department of Pediatrics and Child Health, Hawassa, Ethiopia
aff003; Johns Hopkins University, Bloomberg School of Public Health, Department of International Health, Baltimore, Maryland, United States of America
aff004; Lund University, Faculty of Medicine, Department of Health Sciences, Lund, Sweden
aff005
Vyšlo v časopise:
PLoS ONE 14(10)
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pone.0223655
Souhrn
Background
There are limited data on the treatment outcomes of adolescents living with HIV. Our objective was to compare mortality and loss to follow up (LTFU) rates between adolescent and younger age groups at enrollment in care.
Methods
This was a retrospective cohort study carried out in eight health facilities in two regions of Ethiopia. Adolescents (age 10–14 and 15–19 year) and children (age 0–9 year) enrolled in chronic HIV care between 2005 and 2013 constituted the study population. We reviewed the individual patient charts between March and June 2014 and updated the data on the status of each patient through December 2015. We used death and loss-to-follow up as primary endpoints and used the Cox-regression analysis where age, categorized as adolescent versus child, was the main predictor variable.
Results
Of 2058 participants studied, 52.1% were adolescents. The cohort contributed 2422 person-years of observation (PYO) during the pre-ART follow-up, whereas 1531 patients put on ART contributed 5984 PYO. Of those put on ART, 209 (13.7%) LTFU and 92 (6%) deaths were reported. Adolescents in age group 15–19 yr had the highest risk of LTFU [adjusted hazard ratio, aHR (95% CI) = 3.1 2.1, 5.0 ] followed by those in age group 10–14 yr (aHR = 1.5 [0.9, 2.3]) compared with children aged 0–9 yr. Mortality hazard was significantly higher among younger adolescents (aHR = 2.8 [1.4, 5.4]) and older adolescents (aHR = 2.3 [1.1, 4.9]) compared with children.
Conclusions
Adolescents are at higher risk of mortality and LTFU as compared to children ages 0–9. Younger adolescents and children had similar LTFU rates. Narrow age band disaggregated analysis can serve as useful guide for tailoring interventions to the specific needs of different age groups.
Klíčová slova:
Death rates – Cohort studies – Age groups – HIV infections – Ethiopia – Adolescents – HIV epidemiology
Zdroje
1. Gore FM, Bloem PJ, Patton GC, Ferguson J, Joseph V, Coffey C et al (2011): Global burden of disease in young people aged 10–24 years: a systematic analysis. Lancet, 377(9783):2093–2102. doi: 10.1016/S0140-6736(11)60512-6 21652063
2. Dick B, Ferguson BJ (2015): Health for the World's Adolescents: A Second Chance in the Second Decade. J Adolesc Health, 56(1):3–6. doi: 10.1016/j.jadohealth.2014.10.260 25530601
3. Joint United Nations Programme on HIV/AIDS (2014). 90–90–90: an ambitious treatment target to help end the AIDS epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS.
4. Joint United Nations Programme on HIV/AIDS (2018). Global AIDS update 2018. Miles to go. Closing gaps. Breaking barriers. Righting injustices. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS.
5. Worl Health Organization (2015). Global health estimates: deaths by cause, age, sex, by country and by region, 2000–2015. Geneva, Switzerland: World Health Organization; 2016.
6. Wong V. J., Murray K. R., Phelps B. R., Vermund S. H., McCarraher D. R (2017). Adolescents, young people, and the 90-90-90 goals: a call to improve HIV testing and linkage to treatment. AIDS, 31 Suppl 3(Suppl 3), S191–S194.
7. Slogrove AL, Sohn AH (2018): The global epidemiology of adolescents living with HIV: time for more granular data to improve adolescent health outcomes. Curr Opin HIV AIDS, 13(3):170–178. doi: 10.1097/COH.0000000000000449 29432227
8. Stover J, Walker N, Grassly NC, Marston M (2006): Projecting the demographic impact of AIDS and the number of people in need of treatment: updates to the Spectrum projection package. Sex Transm Infect;82 Suppl 3:iii45–50.
9. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F (2004): Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 364(9441):1236–1243. doi: 10.1016/S0140-6736(04)17140-7 15464184
10. Slogrove AL, Schomaker M, Davies MA, Williams P, Balkan S, Ben-Farhat J, Calles N (2018). The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis. PLoS Med, 15(3):e1002514. doi: 10.1371/journal.pmed.1002514 29494593
11. Nglazi MD, Kranzer K, Holele P, Kaplan R, Mark D, Jaspan H, et al (2012). Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa. BMC Infect Dis, 12:21. doi: 10.1186/1471-2334-12-21 22273267
12. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, et al (2009). Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr.51(1):65–71. doi: 10.1097/QAI.0b013e318199072e 19282780
13. Charles M, Noel F, Leger P, Severe P, Riviere C, Beauharnais CA, et al (2008). Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. Bull World Health Organ, 86(12):970–977. doi: 10.2471/BLT.07.050120 19142298
14. Bakanda C, Birungi J, Mwesigwa R, Nachega JB, Chan K, Palmer A, et al (2011). Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda. PLoS One, 6(4):e19261. doi: 10.1371/journal.pone.0019261 21559441
15. CIPHER Global Cohort Collaboration (2018). Inequality in outcomes for adolescents living with perinatally acquired HIV in sub-Saharan Africa: a Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Cohort Collaboration analysis. J Int AIDS Soc, 21 Suppl 1.
16. Central Statistical Agency/Ethiopia, ICF International: Ethiopia Demographic and Health Survey 2011. Addis Ababa, Ethiopia: Central Statistical Agency/Ethiopia and ICF International; 2012.
17. Mulissa Z., Jerene D., & Lindtjørn B. (2010). Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. PLoS ONE, 5(10), e13268–e13268. doi: 10.1371/journal.pone.0013268 20949010
18. Nglazi MD, Kranzer K, Holele P, Holele P, Kaplan R, Mark D, Jaspan H. et al. Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa. BMC Infect Dis 2012, 12(1):21–27.
19. Kranzer K, Bradley J, Musaazi J, Nyathi M, Gunguwo H, Ndebele W, et al (2017): Loss to follow-up among children and adolescents growing up with HIV infection: age really matters. J Int AIDS Soc, 20(1):1–7.
20. Nabukeera-Barungi N, Elyanu P, Asire B, Asire B, Katureebe C, Lukabwe I, et al (2015): Adherence to antiretroviral therapy and retention in care for adolescents living with HIV from 10 districts in Uganda. BMC Infect Dis, 15:520. doi: 10.1186/s12879-015-1265-5 26573923
21. Okoboi S, Ssali L, Yansaneh AI, Bakanda C, Birungi J, Nantume S, et al (2016): Factors associated with long-term antiretroviral therapy attrition among adolescents in rural Uganda: a retrospective study. J Int AIDS Soc, 19(5 Suppl 4):20841.
22. Chaudhury S, Hertzmark E, Muya A, Sando D, Ulenga N, Machumi L, et al (2018): Equity of child and adolescent treatment, continuity of care and mortality, according to age and gender among enrollees in a large HIV programme in Tanzania. J Int AIDS Soc, 21 Suppl 1.
23. Castilho JL, Melekhin VV, Sterling TR (2014): Sex Differences in HIV Outcomes in the Highly Active Antiretroviral Therapy Era: A Systematic Review. AIDS Res Hum Retroviruses, 30(5):446–456. doi: 10.1089/AID.2013.0208 24401107
24. Biru M, Hallstrom I, Lundqvist P, Jerene D (2018): Rates and predictors of attrition among children on antiretroviral therapy in Ethiopia: A prospective cohort study. PLoS One, 13(2):e0189777. doi: 10.1371/journal.pone.0189777 29408897
25. Jerene D, Endale A, Hailu Y, Lindtjorn B (2006): Predictors of early death in a cohort of Ethiopian patients treated with HAART. BMC Infect Dis, 6:136. doi: 10.1186/1471-2334-6-136 16948852
26. Enane LA, Vreeman RC, Foster C (2018): Retention and adherence: global challenges for the long-term care of adolescents and young adults living with HIV. Curr Opin HIV AIDS, 13(3):212–219. doi: 10.1097/COH.0000000000000459 29570471
27. Chaiyachati KH, Ogbuoji O, Price M, Suthar AB, Negussie EK, Bärnighausen T (2014): Interventions to improve adherence to antiretroviral therapy: a rapid systematic review. AIDS, 28 Suppl 2:S187–204.
28. Desmonde S., Tanser F., Vreeman R., Takassi E., Edmonds A., Lumbiganon P., et al (2018). Access to antiretroviral therapy in HIV-infected children aged 0–19 years in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Global Cohort Consortium, 2004–2015: A prospective cohort study. PLoS Med, 15(5), e1002565. doi: 10.1371/journal.pmed.1002565 29727458
29. Kariminia A., Law M., Davies M. A., Vinikoor M., Wools-Kaloustian K., Leroy et al (2018). Mortality and losses to follow-up among adolescents living with HIV in the IeDEA global cohort collaboration. J Int AIDS Soc, 21(12), e25215. doi: 10.1002/jia2.25215 30548817
30. Biru M., Lunqvist P., Molla M., Jerene D., & Hallstrom I. (2017). Hope for the Future But Fear the Risk of Stigma: Ethiopian Family Caregivers' Lived Experience of Caring for Their HIV Positive Child Two Years After Starting Antiretroviral Treatment. Compr Child Adolesc Nurs, 1–17. doi: 10.1080/24694193.2017.1386964
Článok vyšiel v časopise
PLOS One
2019 Číslo 10
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Nejasný stín na plicích – kazuistika
- Masturbační chování žen v ČR − dotazníková studie
- Těžké menstruační krvácení může značit poruchu krevní srážlivosti. Jaký management vyšetření a léčby je v takovém případě vhodný?
- Fixní kombinace paracetamol/kodein nabízí synergické analgetické účinky
Najčítanejšie v tomto čísle
- Correction: Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study
- Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
- Experimentally validated simulation of coronary stents considering different dogboning ratios and asymmetric stent positioning
- Risk factors associated with IgA vasculitis with nephritis (Henoch–Schönlein purpura nephritis) progressing to unfavorable outcomes: A meta-analysis